Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: HBI-8000|DRUG: Trastuzumab|DRUG: Paclitaxel
Sponsor: HUYABIO International, LLC.